Introduction

Name

• IUPAC.

Class of drug

• Antidepressant.
• Selective serotonin re-uptake inhibitor (SSRI) class.

Description

Chemical name

• (RS)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine

Molecular formula

• C17H18F3NO-HCl

Molecular weight

• 345.79

Physical properties

• White to off-white crystalline solid.
• Water Solubility: 14 mg/mL.
• Octanol-water Partition Coefficient (log P, pH 7): 4.1.
• Product as packaged for sale:
• 8, 16, 32 and 64 mg tablets, in bottles containing 30 tablets - approved for veterinary use in dogs in the US.
• 10 mg tablets - not approved for veterinary use.
• 10, 20 and 40 mg tablets - not approved for veterinary use.
• 4 mg/mL syrup - not approved for veterinary use.

Storage requirements

• Veterinary product as packaged for sale:
  • Store at 20-25ºC (68-77ºF).
  • Excursions permitted between 15-30ºC (59-86ºF).
  • Do not remove desiccant canister from the bottle.

Uses

Indications

• Treatment of canine separation anxiety Separation anxiety , in conjunction with a behavior modification plane:
  • Approved for use the US.
• Treatment of aberrant compulsive behaviors Stereotype behavior , eg lick granulomas, self-mutilation, psychogenic pruritus/alopecia.
• Dominance aggression in dogs Intraspecific intolerance.

Administration

Precautions

Interactions

with other drugs

• Mixed function oxidase (cytochrome P450) inhibitor - administer with care with other agents undergoing hepatic metabolism. A washout period of 6 weeks may be required before commencing other treatment due to the long half-lives of fluoxetine and norfluoxetine.
• Do not give in combination with a monoamine oxidase inhibitor (MAOI) for example, selegiline hydrochloride Selegiline hydrochloride (L-deprenyl) or amitraz Amitraz , or within a minimum of 14 days of discontinuing therapy with an MAOI.
• Do not give concomitantly with drugs that lower the seizure threshold (eg phenothiazines such as acepromazine Acepromazine maleate or chlorpromazine).
• Use with care concomitantly with aspirin Acetyl salicylic acid or other anticoagulants.

Adverse Reactions

Further Reading

Publications

Refereed papers

• Recent references from PubMed and VetMedResource.
• Fitzgerald K T, Bronstein A C (2013) Selective serotonin reuptake inhibitor exposure. Top Companion Anim Med 28 (1), 13-17 PubMed.
• Thomas D E, Lee J A, Hovda L R (2012) Retrospective evaluation of toxicosis from selective serotonin reuptake inhibitor antidepressants: 313 dogs (2005-2010). J Vet Emerg Crit Care 22 (6), 674-681 PubMed.
• Kukanich B, Kukanich K S, Rodriguez J R (2011) The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. Vet Anaesth Analg 38 (3), 224-230 PubMed.
• Rosado B, García-Belenguer S, León M et al (2011) Effect of fluoxetine on blood concentrations of serotonin, cortisol and dehydroepiandrosterone in canine aggression. J Vet Pharmacol Ther 34 (5), 430-436 PubMed.
• Yalcin E (2010) Comparison of clomipramine and fluoxetine treatment of dogs with tail chasing. Tierarztl Prax Ausg K Kleintiere Heimtiere 38 (5), 295-299 PubMed.
• Irimajiri M, Luescher A U, Douglass G et al (2009) Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs. J Am Vet Med Assoc 235 (6), 705-709 PubMed.
• Simpson B S, Landsberg G M, Reisner I R et al (2007) Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet Ther 8 (1), 18-31 PubMed.
• Jöchle W (1998) [Abnormal behavior and adaptation problems in dogs and cats and their pharmacological control.] Tierarztl Prax Ausg K Klientiere Heimtiere 26 (6), 410-421 PubMed.
• Wynchank D & Berk M (1998) Fluoxetine treatment of acral lick dermatitis in dogs - a placebo control randomised double blind trial. Depress Anxiety 8 (1), 21-23 PubMed.
• Wynchank D & Berk M (1998) Behavioral changes in dogs with acral lick dermatitis during a 2-month extension phase of fluoxetine treatment. Hum Psychopharmacol Clin Exp 13 (6), 435-437 Wiley Online Library.
• Pohland R C & Bernhard N R (1997) Postmortem serum and tissue redistribution of fluoxetine and norfluoxetine in dogs following oral administration of fluoxetine hydrochloride (Prozac). J Forensic Sci 42 (5), 812-816 PubMed.
• Rapaport J L, Ryland D H & Kriete M (1992) Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 49 (7), 517-521 PubMed.

Other sources of information

• Product information http://www.drugs.com/pro/reconcile.html
• Product website http://www.reconcile.com/
• BSAVA Small Animal Formulary. Ed. I Ramsey. (2008) 6th edn. Cheltenham: BSAVA. pp 142-143.